# Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab

Source: https://onco.cc/trials/nct06371807/  
OnCo record `nct06371807` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pembrolizumab in triple-negative breast cancer, run by Fundacao Champalimaud, not yet recruiting.

## Summary

Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab is a phase 2, randomised interventional study registered as NCT06371807 by Fundacao Champalimaud, with a registry enrolment figure of 20 participants, started 2024-07 and due to reach its primary completion in 2025-07. Interventions recorded: Pembrolizumab injection. Conditions listed: Early Breast Cancer; Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Have locally histologically confirmed diagnosis of invasive carcinoma of the breast that is classified as TNBC, as defined by the most recent ASCO/CAP guidelines". Sites: Portugal. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: KEYPARTNER
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06371807
- Phase: 2
- Setting: Immunogenicity Profile of Neoadjuvant Keytruda in Combination With Anthracycline Versus Carboplatin/PAclitaxel Containing Chemotherapy Regimen for The Treatment of Early-stage, TILs-Positive, Triple-Negative Breast CanceR
- Sponsor: Fundacao Champalimaud
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06371807: https://clinicaltrials.gov/study/NCT06371807

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06371807.json